Symyx Technologies has announced the latest release of the Symyx Metabolite database.
A large collection of drug metabolism data is now available to pharmaceutical, agrochemical, and biotechnology researchers via the Symyx Isentris data access, analysis, and decision support system, as well as the web-based Discoverygate content platform.
With Isentris, pharmacologists and medicinal chemists can explore metabolic biotransformation pathways in ways previously not possible.
Combining in-house and Symyx Metabolite data, scientists can navigate through possible biotransformation routes generated from known metabolites, intermediates, and their known transformations.
As biotransformation pathways are explored, Isentris also informs scientists if there are additional toxic, physicochemical, or biological properties known about the metabolites and their intermediates.
Scientists can drill down to related molecule information to further explore and report on possible adverse effects or properties as a result of metabolism.
As scientists browse in-house molecule information, they can launch the biotransformation explorer in Symyx Isentris to investigate metabolic pathways and gain further insight into compounds of interest and their metabolic fate.
Isentris eliminates the hard work of manually exploring and linking the data, enabling scientists to make rapid and more accurate assessments of pharmacological compounds.
Symyx Metabolite provides coverage of xenobiotic transformations and metabolic schemes from respected published sources, as well as non-proprietary metabolism studies from new drug applications published by the US Food and Drug Administration.
This information is designed to help researchers better understand degradation pathways of known compounds within humans and lab animals.
